Literature DB >> 16828217

Amphetamine and pentylenetetrazole given post-trial 1 enhance one-trial tolerance to the anxiolytic effect of diazepam in the elevated plus-maze in mice.

Kleber Meneghel Vargas1, Cláudio Da Cunha, Roberto Andreatini.   

Abstract

There are several hypotheses to explain the lack of an anxiolytic effect on animals with previous maze experience (one-trial tolerance). Some of these hypotheses are related to learning and memory, so the reduction of trial 1 duration to 1 min or amnesic drug administration before trial 1 prevents the lack of an anxiolytic effect in trial 2. Amphetamine and pentylenetetrazole have been shown to enhance memory consolidation when administered immediately after training. Thus, the aim of the present study was to evaluate the effect of amphetamine (1.0-3.0 mg/kg) or pentylenetetrazole (30.0 mg/kg), at putative memory-enhancing doses, on the effect of diazepam (2.5 mg/kg) in the elevated plus-maze trial 2 on mice exposed to a 1-min long trial 1. Mice were submitted to 1-min trial 1 in the elevated plus-maze immediately followed by drug treatment (saline, amphetamine, or pentylenetetrazole) and to elevated plus-maze trial 2 after 48 h. Animals were treated with vehicle or diazepam 30 min before trial 2. The results showed that post-trial 1 saline and 1.0 mg/kg amphetamine did not induce one-trial tolerance. On the other hand, 2.0 and 3.0 mg/kg amphetamine and 30 mg/kg pentylenetetrazole induced a lack of anxiolytic effect of diazepam on trial 2 even with 1-min trial 1 length. Furthermore, these data were not due to novelty exposure in trial 1 or to amphetamine treatment so that mice exposed to an activity chamber instead of the plus-maze (trial 1) and then immediately submitted to amphetamine treatment (2.0 mg/kg) did not show one-trial tolerance 48 h after trial 1. Taken as a whole, these data support the hypothesis that memory is involved in the lack of an anxiolytic effect in the elevated plus-maze trial 2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828217     DOI: 10.1016/j.pnpbp.2006.05.004

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

1.  Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.

Authors:  Shao-wen Tian; Moshe Laudon; Li Han; Jun Gao; Fu-lian Huang; Yu-feng Yang; Hai-feng Deng
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

2.  Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat.

Authors:  Santiago J Ballaz; Michel Bourin; Huda Akil; Stanley J Watson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-09-14       Impact factor: 5.067

3.  Hypoxic-ischemic injury decreases anxiety-like behavior in rats when associated with loss of tyrosine-hydroxylase immunoreactive neurons of the substantia nigra.

Authors:  Hei Ming-Yan; Ya-Li Luo; Xiao-Chun Zhang; Hong Liu; Ru Gao; Jing-Jiang Wu
Journal:  Braz J Med Biol Res       Date:  2011-12-09       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.